Trial Profile

The impact of rifaximin on the NHS hospital resource use associated with the management of patients with hepatic encephalopathy (HE): a retrospective observational study

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 25 May 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

21 Apr 2017 According to a Norgine media release, data was presented at The International Liver Congress in April 2017.
02 Nov 2016 Results assessing the impact of rifaximin-aplha on the costs associated with hospital admissions and attendances in patients with Hepatic-encephalopathy, presented at the 19th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.
31 Oct 2016 Results published in Norgine media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com